Key facts
- It has raised $83.0M; the latest was Later Stage VC ($58.8M) in Sep 2024.
- Notable investors include Innovate UK, 5Y Capital, BGF (Financial Services), Parkwalk Advisors, Cambridge Angels — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for PhoreMost
- ·The full record, as it builds
Funding rounds
No funding rounds for PhoreMost are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PhoreMost
Operator of a drug target identification and drug discovery company, intended to identify new targets or drugs for future therapy. The company's platform provides cryptic druggable sites in the human genome and directly links them to useful therapeutic functions in a live-cell context, and then uses these functionally validated protein fragments to inform the design of small molecule drugs with the same shape, enabling medical practitioners to continue the pipeline of highly validated first-in-class drug discovery programs for out-licensing to pharma.
- Sector
- Healthcare
- HQ
- Pampisford, United Kingdom
- Founded
- 2014
- Employees
- 38
- Website
- phoremost.com/
- Ownership
- Privately Held (backing)
PhoreMost doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PhoreMost shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PhoreMost in its N-PORT filings yet. We sweep new filings monthly.